Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes
Gheibi, Sevda LU ; Singh, Tania LU ; da Cunha, Joao Paulo M. C. M. LU
; Fex, Malin
LU
and Mulder, Hindrik
LU
(2020)
In Cells
9(11).
- Abstract
- Type 2 diabetes, characterized by dysfunction of pancreatic β-cells and insulin resistance in peripheral organs, accounts for more than 90% of all diabetes. Despite current developments of new drugs and strategies to prevent/treat diabetes, there is no ideal therapy targeting all aspects of the disease. Restoration, however, of insulin-producing β-cells, as well as insulin-responsive cells, would be a logical strategy for the treatment of diabetes. In recent years, generation of transplantable cells derived from stem cells in vitro has emerged as an important research area. Pluripotent stem cells, either embryonic or induced, are alternative and feasible sources of insulin-secreting and glucose-responsive cells. This notwithstanding,... (More)
- Type 2 diabetes, characterized by dysfunction of pancreatic β-cells and insulin resistance in peripheral organs, accounts for more than 90% of all diabetes. Despite current developments of new drugs and strategies to prevent/treat diabetes, there is no ideal therapy targeting all aspects of the disease. Restoration, however, of insulin-producing β-cells, as well as insulin-responsive cells, would be a logical strategy for the treatment of diabetes. In recent years, generation of transplantable cells derived from stem cells in vitro has emerged as an important research area. Pluripotent stem cells, either embryonic or induced, are alternative and feasible sources of insulin-secreting and glucose-responsive cells. This notwithstanding, consistent generation of robust glucose/insulin-responsive cells remains challenging. In this review, we describe basic concepts of the generation of induced pluripotent stem cells and subsequent differentiation of these into pancreatic β-like cells, myotubes, as well as adipocyte- and hepatocyte-like cells. Use of these for modeling of human disease is now feasible, while development of replacement therapies requires continued efforts. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/973aad98-9cb5-47d6-9b76-112d680c44ca
- author
- Gheibi, Sevda
LU
; Singh, Tania
LU
; da Cunha, Joao Paulo M. C. M.
LU
; Fex, Malin
LU
and Mulder, Hindrik
LU
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cells
- volume
- 9
- issue
- 11
- article number
- 2465
- publisher
- MDPI AG
- external identifiers
-
- scopus:85096279051
- pmid:33198288
- ISSN
- 2073-4409
- DOI
- 10.3390/cells9112465
- language
- English
- LU publication?
- yes
- id
- 973aad98-9cb5-47d6-9b76-112d680c44ca
- date added to LUP
- 2020-11-14 11:59:47
- date last changed
- 2022-08-19 00:31:16
@article{973aad98-9cb5-47d6-9b76-112d680c44ca,
abstract = {{Type 2 diabetes, characterized by dysfunction of pancreatic β-cells and insulin resistance in peripheral organs, accounts for more than 90% of all diabetes. Despite current developments of new drugs and strategies to prevent/treat diabetes, there is no ideal therapy targeting all aspects of the disease. Restoration, however, of insulin-producing β-cells, as well as insulin-responsive cells, would be a logical strategy for the treatment of diabetes. In recent years, generation of transplantable cells derived from stem cells in vitro has emerged as an important research area. Pluripotent stem cells, either embryonic or induced, are alternative and feasible sources of insulin-secreting and glucose-responsive cells. This notwithstanding, consistent generation of robust glucose/insulin-responsive cells remains challenging. In this review, we describe basic concepts of the generation of induced pluripotent stem cells and subsequent differentiation of these into pancreatic β-like cells, myotubes, as well as adipocyte- and hepatocyte-like cells. Use of these for modeling of human disease is now feasible, while development of replacement therapies requires continued efforts.}},
author = {{Gheibi, Sevda and Singh, Tania and da Cunha, Joao Paulo M. C. M. and Fex, Malin and Mulder, Hindrik}},
issn = {{2073-4409}},
language = {{eng}},
number = {{11}},
publisher = {{MDPI AG}},
series = {{Cells}},
title = {{Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes}},
url = {{http://dx.doi.org/10.3390/cells9112465}},
doi = {{10.3390/cells9112465}},
volume = {{9}},
year = {{2020}},
}